» Articles » PMID: 35897644

Lipoprotein Profile in Immunological Non-Responders PLHIV After Antiretroviral Therapy Initiation

Abstract

Nuclear magnetic resonance (NMR)-based advanced lipoprotein tests have demonstrated that LDL and HDL particle numbers (LDL-P and HDL-P) are more powerful cardiovascular (CV) risk biomarkers than conventional cholesterol markers. Of interest, in people living with HIV (PLHIV), predictors of preclinical atherosclerosis and vascular dysfunction may be associated with impaired immune function. We previously stated that immunological non-responders (INR) were at higher CV risk than immunological responders (IR) before starting antiretroviral therapy (ART). Using Liposcale tests, we characterized the lipoprotein profile from the same cohort of PLHIV at month 12 and month 36 after starting ART, intending to explore what happened with these indicators of CV risk during viral suppression. ART initiation dissipates the differences in lipoprotein-based CV risk markers between INR and IR, and only an increase in the number of HDL-P was found in INR + IR when compared to controls ( = 0.047). Interestingly, CD4 T-cell counts negatively correlated with medium HDL-P concentrations at month 12 in all individuals (ρ = -0.335, = 0.003). Longitudinal analyses showed an important increase in LDL-P and HDL-P at month 36 when compared to baseline values in both IR and INR. A proper balance between a proatherogenic and atherogenic environment may be related to the reconstitution of CD4 T-cell count in PLHIV.

Citing Articles

Human Immunodeficiency Virus as a Risk Factor for Cardiovascular Disease.

Lembas A, Zaleski A, Peller M, Mikula T, Wiercinska-Drapalo A Cardiovasc Toxicol. 2023; 24(1):1-14.

PMID: 37982976 PMC: 10838226. DOI: 10.1007/s12012-023-09815-4.


Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV.

Espineira S, Flores-Pinas M, Chafino S, Vilades C, Negredo E, Fernandez-Arroyo S Front Immunol. 2023; 14:1228795.

PMID: 37649488 PMC: 10465175. DOI: 10.3389/fimmu.2023.1228795.


Special Issue: New Insight into the Molecular Role of Lipids and Lipoproteins in Vascular Diseases.

Benitez S, Sanchez-Quesada J Int J Mol Sci. 2023; 24(13).

PMID: 37445837 PMC: 10341864. DOI: 10.3390/ijms241310659.

References
1.
Pichler G, Amigo N, Tellez-Plaza M, Pardo-Cea M, Dominguez-Lucas A, Marrachelli V . LDL particle size and composition and incident cardiovascular disease in a South-European population: The Hortega-Liposcale Follow-up Study. Int J Cardiol. 2018; 264:172-178. DOI: 10.1016/j.ijcard.2018.03.128. View

2.
Liang C, Gowda S, Gowda D, Sakurai T, Sazaki I, Chiba H . Simple and Sensitive Method for the Quantitative Determination of Lipid Hydroperoxides by Liquid Chromatography/Mass Spectrometry. Antioxidants (Basel). 2022; 11(2). PMC: 8868426. DOI: 10.3390/antiox11020229. View

3.
Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo L . Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009; 5:757-65. PMC: 2747394. View

4.
Burdo T, Lo J, Abbara S, Wei J, DeLelys M, Preffer F . Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011; 204(8):1227-36. PMC: 3203384. DOI: 10.1093/infdis/jir520. View

5.
Azzoni L, Foulkes A, Firnhaber C, Yin X, Crowther N, Glencross D . Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011; 14:37. PMC: 3163506. DOI: 10.1186/1758-2652-14-37. View